Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency

Rhea-AI Summary

Cellyan Biotechnology (Nasdaq: HKPD) received a Nasdaq notice dated Jan 12, 2026 that its closing bid price was below the $1.00 minimum for 30 consecutive business days (Nov 26, 2025–Jan 9, 2026), resulting in noncompliance with Nasdaq rule 5550(a)(2).

The company’s listing remains active and trading is uninterrupted. Cellyan has a 180-calendar-day cure period until July 13, 2026 to regain a $1.00 closing bid for 10 consecutive business days or seek a second 180-day period by meeting other Capital Market listing standards and notifying Nasdaq.

Positive

• Listing remains active and shares continue to trade uninterrupted on Nasdaq
• Company has a 180-day compliance window through July 13, 2026 to cure the deficiency

Negative

• Closing bid price below $1.00 for 30 consecutive business days (Nov 26, 2025–Jan 9, 2026)
• Risk of needing a reverse share split or additional cure steps if compliance not regained
• Possible eligibility for delisting if compliance and listing standards are not met after cure periods

News Market Reaction – HKPD

+0.01%

1 alert

+0.01% News Effect

+$877 Valuation Impact

$9M Market Cap

0.0x Rel. Volume

On the day this news was published, HKPD gained 0.01%, reflecting a mild positive market reaction. This price movement added approximately $877 to the company's valuation, bringing the market cap to $9M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Nasdaq minimum bid: US$1.00 per share Non-compliance period: 30 consecutive business days Initial compliance window: 180 calendar days +5 more

8 metrics

Nasdaq minimum bid US$1.00 per share Minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)

Non-compliance period 30 consecutive business days Closing bid below US$1.00 from Nov 26, 2025 to Jan 9, 2026

Initial compliance window 180 calendar days Period until July 13, 2026 to regain minimum bid compliance

Compliance trading requirement 10 consecutive business days Bid must be US$1.00 or above for matter to be closed

Additional grace period 180 calendar days Potential second compliance period if initial window fails

Reverse split deadline 10 business days prior Reverse split must be completed at least 10 business days before period end

Par value per share US$0.001 Par value of each Class A ordinary share referenced in notice

Market capitalization $8,767,000 Pre-notice market cap from market context

Market Reality Check

Price: $0.6600 Vol: Volume 7,149 is at 0.18x ...

low vol

$0.6600 Last Close

Volume Volume 7,149 is at 0.18x the 20-day average of 38,681, indicating muted trading interest before this notice. low

Technical Shares at 0.7986 trade below the 200-day MA of 1.18, sitting 78.93% below the 52-week high of 3.79 and 17.44% above the 52-week low of 0.68.

Peers on Argus

HKPD was nearly flat at -0.01% while peers showed mixed moves: SCNX +3.03%, SSY ...

HKPD was nearly flat at -0.01% while peers showed mixed moves: SCNX +3.03%, SSY +9.31%, PETS -1.47%, WGRX +2.42%, HITI +2%. The bid-price deficiency notice appears stock-specific rather than part of a sector-wide move.

Historical Context

1 past event · Latest: Dec 17 (Neutral)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Dec 17	Annual meeting results	Neutral	-1.8%	Shareholders approved capital increase, share class redesignation, and reverse split authority.

Pattern Detected

Only one prior recent news event with a modest -1.84% reaction, insufficient to define a clear pattern.

Recent Company History

Recent disclosures show HKPD undergoing significant corporate restructuring. At the December 12, 2025 annual meeting, shareholders approved an increase in authorized share capital to US$1,000,000 (up to 1,000,000,000 shares), redesignation into Class A and Class B ordinary shares, authorization for a reverse share split/share consolidation, and a corporate name change to Cellyan Biotechnology Co., Ltd. A related 6-K detailed authorization for a reverse split ratio between one-for-ten and one-for-one hundred. Today’s Nasdaq bid-price deficiency notice reflects listing pressures that were already highlighted in prior filings.

Market Pulse Summary

This announcement formalizes that HKPD’s shares traded below the US$1.00 minimum bid for 30 consecut...

Analysis

This announcement formalizes that HKPD’s shares traded below the US$1.00 minimum bid for 30 consecutive business days, triggering a Nasdaq deficiency notice. The company has 180 days, potentially plus another 180, to regain compliance by maintaining a bid at or above US$1.00 for at least 10 consecutive business days. Prior shareholder approvals around capital structure changes provide context, and investors may track any disclosed plans to address listing requirements.

Key Terms

reverse share split, nasdaq capital market, deficiency notification, closing bid price, +1 more

5 terms

reverse share split financial

"including by effecting a reverse share split, if necessary."

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

nasdaq capital market regulatory

"meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

deficiency notification regulatory

"receipt of a deficiency notification."

A deficiency notification is a formal notice from a regulator, exchange, or reviewer pointing out missing, unclear, or inadequate information in a company’s filing or application. It matters to investors because it can delay approvals, listings, fundraising or product launches and signal compliance or disclosure problems; think of it as a teacher returning a homework sheet with items circled that must be fixed before the work is accepted.

closing bid price financial

"the closing bid price of the Company's class A ordinary shares ... was below the minimum requirement"

The closing bid price is the last price that a buyer was willing to pay for a security at the end of the trading day. It reflects the final visible demand for the stock — like the last offer someone makes for a used car before a yard closes — and helps investors gauge market interest, set valuations, and mark portfolios to market for that day.

publicly held shares financial

"continued listing requirement for market value of publicly held shares"

Shares that are publicly held are portions of a company that any investor can buy or sell on public markets, like slices of a pie owned by many people rather than a few insiders. They matter because they determine how easy it is to trade the stock, influence company control through voting and can affect price swings and dividend payments as supply and demand change in the market.

AI-generated analysis. Not financial advice.

HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the “Notification Letter”) dated January 12, 2026 from Nasdaq's Listing Qualifications Department indicating that the closing bid price of the Company's class A ordinary shares of par value of US$0.001 each was below the minimum requirement of US$1.00 per share for 30 consecutive business days from November 26, 2025 through January 9, 2026, and the Company was therefore currently not in compliance with the minimum bid price requirement set forth under Nasdaq listing rule 5550(a)(2). 

The notification letter has no immediate effect on the listing of the Company’s class A ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker “HKPD”.

Pursuant to listing rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until July 13, 2026, to regain compliance with the minimum bid price rule. If, at any time during the 180-day period the closing bid price per share of the Company’s class A ordinary shares is US$1.00 or above for a minimum of ten consecutive business days, Nasdaq will provide written confirmation of compliance and this matter will be closed.

In the event the Company does not regain compliance with the minimum bid price requirement by July 13, 2026, the Company may be eligible for an additional 180 calendar day grace period to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, including by effecting a reverse share split, if necessary. If the Company chooses to implement a reverse share split, it must complete the split no later than 10 business days prior to July 13, 2026 or the expiration of the second compliance period if granted.

This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The Company is currently looking into various options available with respect to regaining such compliance. The notification letter has no effect at this time on the listing of the Company's class A ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker “HKPD.”

About Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd (f.k.a. Hong Kong Pharma Digital Technology Holdings Limited) offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.

Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China.

Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers. 

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. All forward-looking statements, expressed or implied, in this release are based only on information currently available to us and speak only as of the date on which they are made. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this release. Except as otherwise required by applicable law, we disclaim any duty to publicly update any forward-looking statement to reflect events or circumstances after the date of this release. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in our filings with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries please contact: 

Cellyan Biotechnology Co., Ltd
Media Contact: andy@cell-yan.com 
Investor Relations: stella @cell-yan.com

FAQ

What did Nasdaq notify Cellyan Biotechnology (HKPD) about on January 12, 2026?

Nasdaq notified HKPD that its closing bid price was below the $1.00 minimum for 30 consecutive business days, triggering noncompliance with rule 5550(a)(2).

How long does Cellyan (HKPD) have to regain compliance with the Nasdaq $1.00 bid rule?

Cellyan has a 180-calendar-day period until July 13, 2026 to regain compliance by achieving a $1.00 closing bid for 10 consecutive business days.

Will Cellyan (HKPD) be delisted immediately after the Nasdaq notice?

No. The notice has no immediate effect on the listing and shares will continue to trade while the company uses the 180-day cure period.

What options can Cellyan (HKPD) use to regain Nasdaq compliance?

Options include market recovery to a $1.00 closing bid, or if needed, executing a reverse share split and meeting other Nasdaq Capital Market standards.

If Cellyan (HKPD) fails to cure by July 13, 2026, what happens next?

The company may be eligible for a second 180-day grace period only if it notifies Nasdaq and meets other initial listing standards excluding the bid price requirement.